TheBrief.Health

FDA classified specified INCA infant nasal CPAP set lots as Class I due to potentially loose connections, requiring stock removal and uninterrupted respiratory support.

FDA classified Medline convenience kits containing BD ChloraPrep applicators as Class I due to fungal contamination risks, prompting quarantine, exposure tracing, and clinical evaluation.

FDA granted accelerated approval to dostarlimab for untreated MSI-H or dMMR locally advanced rectal cancer, offering eligible patients potential organ preservation while requiring long-term confirmation.

FDA classified a recall of convenience kits containing potentially nonsterile saline flush ampules as Class I, warning of serious infection, sepsis, thrombosis, and organ dysfunction.

FDA granted accelerated approval to dostarlimab for untreated stage II or III MSI-H or dMMR rectal cancer, highlighting early biomarker testing and potential organ preservation.

FDA added a boxed warning for ferric carboxymaltose due to severe, prolonged hypophosphatemia, emphasizing patient risk assessment, symptom education, phosphate correction, and monitoring.

Par Health recalled two dexmedetomidine injection lots after particulate contamination was identified, prompting healthcare facilities to quarantine affected stock, trace exposure, and assess patients.

FDA classified AVID Medical’s correction of convenience kits containing Huons sodium chloride ampules as Class I, prompting quarantine, exposure tracing, and patient assessment.

FDA approved atezolizumab plus chemotherapy after surgery for stage III mismatch-repair-deficient colon cancer, improving three-year disease-free survival and emphasizing biomarker confirmation.

FDA approved imlunestrant plus abemaciclib for ESR1-mutated advanced breast cancer after endocrine progression, making biomarker testing central to treatment selection and monitoring.

FDA classified the Bravo CF delivery-device recall as Class I, prompting facilities to quarantine affected inventory, review scheduled procedures, and arrange alternative reflux-monitoring options.

Tucatinib maintenance approval with trastuzumab and pertuzumab remains unverified in the supplied FDA source, requiring confirmation of eligibility, efficacy, safety, and prescribing guidance.

FDA classified Bravo CF delivery device removal as Class I after 184 serious injuries, prompting inventory verification, procedure reviews, patient assessment, and alternative reflux testing.

FDA classified the Impella introducer correction as Class I following serious bleeding complaints and deaths, prompting inventory checks, heightened hemorrhage vigilance, and reporting.

FDA warned of fungal contamination in certain IV-start kits, prompting facilities to quarantine affected products, trace patient exposures, and assess potential risks of invasive infection.

A randomized study found psilocybin-assisted therapy reduced treatment-resistant depression symptoms through six weeks, supporting further research while long-term durability, safety, and FDA approval remain unresolved.

FDA recalled six lots of compounded glutathione, Myers’ Cocktail, and Tri-Immune Boost injections over elevated endotoxin levels, prompting quarantine, exposure tracing, and clinical assessment.

A 2026 network meta-analysis found SGLT2 inhibitors more consistently reduced heart failure hospitalization, while mortality comparisons remained uncertain and empagliflozin’s arrhythmia signal requires confirmation.

FDA approved tiratricol for peripheral thyrotoxicosis in MCT8 deficiency, targeting excess T3 and cardiovascular effects without establishing reversal of neurological disability.

WHO’s pediatric sickle cell initiative emphasizes implementation, linking early screening, preventive treatment, referral, medicine access, and follow-up to improve equitable care for children.

Baxter recalled one cefazolin in dextrose injection lot over cardboard particles, prompting hospitals to quarantine affected inventory, maintain perioperative antibiotic coverage, and assess potential exposures.

ACHIEVE-5 found oral orforglipron added to titrated insulin glargine improved HbA1c and weight without increasing hypoglycemia, though numerical effect sizes and detailed safety findings remain important.

A randomized pediatric trial found ecopipam reduced Tourette syndrome tic severity versus placebo, supporting further investigation while long-term safety, comparative effectiveness, and FDA approval remain unresolved.

FDA classified the Luna G3 APAP firmware recall as Class I, urging clinics and suppliers to verify affected devices, coordinate corrections, and prevent therapy interruptions.

FDA approved camizestrant for eligible ESR1-mutated advanced breast cancer, enabling mutation-guided endocrine switching before radiographic progression while continuing CDK4/6 inhibitor therapy.